We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+40.06%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$164M
Cap. Flow
+$47.9M
Cap. Flow %
3.88%
Top 10 Hldgs %
53.52%
Holding
82
New
29
Increased
10
Reduced
10
Closed
25

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$49M
2
IMCR icon
Immunocore
IMCR
+$34.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.7M
4
SLN
Silence Therapeutics
SLN
+$23.4M
5
ADVM
Adverum Biotechnologies
ADVM
+$22.8M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$118M
2
ARGX icon
argenx
ARGX
+$55.2M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$35.3M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$29.9M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.89%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
1
CALL
Sarepta Therapeutics
SRPT
$1.7B
$155M 12.57%
1,200,000
+500,000
+71% +$61.2M
ALNY icon
2
CALL
Alnylam Pharmaceuticals
ALNY
$37.8B
$74.7M 6.05%
+500,000
New +$83.4M
IDYA icon
3
IDEAYA Biosciences
IDYA
$3.5B
$65.8M 5.33%
1,500,000
-300,000
-17% -$12.9M
IMCR icon
4
Immunocore
IMCR
$1.78B
$58.5M 4.73%
900,000
+500,000
+125% +$34.3M
IMVT icon
5
Immunovant
IMVT
$8.27B
$57.4M 4.64%
1,775,000
+575,000
+48% +$21M
OCUL icon
6
Ocular Therapeutix
OCUL
$1.91B
$52M 4.21%
5,811,436
+1,811,436
+45% +$12.9M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.7B
$51.8M 4.19%
+400,000
New +$49M
OLMA icon
8
Olema Pharmaceuticals
OLMA
$1.07B
$49.6M 4.02%
4,383,875
– –
DYN icon
9
Dyne Therapeutics
DYN
$4.19B
$49.1M 3.98%
1,730,000
-150,000
-8% -$3.39M
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
$47M 3.81%
800,000
-150,000
-16% -$9.56M
RCKT icon
11
Rocket Pharmaceuticals
RCKT
$356M
$35M 2.83%
1,300,000
+25,000
+2% +$710K
SLN
12
Silence Therapeutics
SLN
$548M
$31.1M 2.52%
1,476,061
+1,076,061
+269% +$23.4M
GPCR icon
13
Structure Therapeutics
GPCR
$3.53B
$30.9M 2.5%
720,058
-350,000
-33% -$14.8M
GERN icon
14
Geron
GERN
$962M
$29.7M 2.4%
+9,000,000
New +$20.2M
CLDX icon
15
Celldex Therapeutics
CLDX
$2.83B
$27.3M 2.21%
+650,000
New +$26.7M
ELVN icon
16
Enliven Therapeutics
ELVN
$3.93B
$26.4M 2.14%
1,574,220
+1,267,144
+413% +$19.4M
VERA icon
17
Vera Therapeutics
VERA
$2.57B
$24.8M 2.01%
+575,000
New +$20.5M
ANNX icon
18
Annexon
ANNX
$867M
$21.9M 1.77%
3,050,000
-1,900,000
-38% -$9.86M
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
$21.2M 1.72%
+1,499,999
New +$22.8M
DSGN icon
20
Design Therapeutics
DSGN
$748M
$20.3M 1.64%
5,032,501
– –
AKRO
21
DELISTED
Akero Therapeutics
AKRO
$20.2M 1.64%
800,000
– –
GPCR icon
22
CALL
Structure Therapeutics
GPCR
$3.53B
$19.3M 1.56%
+450,000
New +$19M
ATXS
23
DELISTED
Astria Therapeutics
ATXS
$17.5M 1.42%
1,244,960
+700,000
+128% +$8.72M
HELP
24
Cybin Inc
HELP
$483M
$16.5M 1.34%
+1,052,632
New +$15.2M
XNCR icon
25
Xencor
XNCR
$1.48B
$14.4M 1.16%
+650,000
New +$14M
1
2 3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2024 Portfolio in Review

As of Q1 2024, Logos Global Management held 82 positions worth $1.24B, up 15% from $1.07B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management deployed $47.9M of net new capital in Q1 2024, opening 29 new positions and adding to 10 existing holdings. Its largest new stake was Sarepta Therapeutics: 400,000 shares worth $51.8M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cytokinetics, an estimated $118M trimmed.

  • Logos Global Management's largest Q1 2024 buy was Sarepta Therapeutics: 400,000 shares worth $51.8M.
  • Logos Global Management added most to Immunocore in Q1 2024, an estimated $34.3M increase.
  • Logos Global Management's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $118M.
  • Logos Global Management fully exited argenx in Q1 2024, selling an estimated $55.2M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q1 2024.
  • Logos Global Management opened 29 new positions and closed 25 in Q1 2024.
  • Logos Global Management's portfolio value rose 15% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q1 2024, filed 15 May 2024.